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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare and highly aggressive hematopoietic
malignancy associated with a poor prognosis. It has been recognized to originate from precursors of
plasmacytoid dendritic cells and has recently been established as a distinct entity. The most frequent
clinical presentations are prominent skin lesions, followed by peripheral blood, bone marrow, and other
organ involvement. Treatment outcomes are often disappointing due to a high relapse rate after
chemotherapy and risk of leukemic dissemination. Herein, we report a case of BPDCN in a 41-year-old
man who presented with cutaneous and nasopharyngeal lesions, and achieved a complete response after
systemic chemotherapy. Dermatologists should be aware of BPDCN and its clinical presentations, as early
diagnosis with appropriate treatment is crucial to improve its prognosis.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previous
known as blastic natural-killer (NK) cell lymphoma and CD4þ/
CD56þ hematodermic neoplasm, is a rare and aggressive hemato-
poietic malignancy with prominent cutaneous involvement and
high risk of leukemic disseminations.1e3 NK cells were previously
regarded as the cells of origin of this neoplasm due to the high
expression levels of CD56 in patients with CD4þ cutaneous lym-
phoma and a distinct blastic cytology.4 However, the lack of other
NK-lineage markers, absence of EpsteineBarr virus (EBV) infection,
and CD4 expression were not typical of NK cell development in
most cases. Therefore, the true NK cell derivation of this tumor was
considered controversial.5 Subsequent studies involving immuno-
phenotypic and functional analyses have shown that the tumor
cells are more likely to be derived from precursors of plasmacytoid
dendritic cells (pDCs).6e8 Therefore, BPDCN is regarded as a distincty have no ﬁnancial or non-
tter or materials discussed in
y, Taipei City Hospital, Heping
ngzheng District, Taipei 100,
iwanese Dermatological Associatioentity and was categorized among “acute myeloid leukemia and
related precursor neoplasm” by the World Health Organization in
2008.9
We herein report a case of BPDCNwith multiple bruise-like skin
lesions on the trunk and face at initial presentation.
Case report
A 41-year-old male patient presented with a 1-month history of
multiple asymptomatic bruise-like lesions on his trunk and face.
Additionally, he developed ecchymotic lesions on the trunk easily
from scratching. He also suffered from several episodes of bleeding
in the right nasal cavity for 1e2 months. He denied having any
underlying systemic disease ormalignancy, except for undergoing a
cholecystectomy 1 year earlier. On physical examination, we noted
multiple 2e3 cm in diameter bluish to violaceous inﬁltrated
patches or plaques scattered on his trunk and a few irregularly
shaped violaceous plaques on his cheeks (Figure 1). There was
neither palpable cervical, axillary, or inguinal superﬁcial lymph-
adenopathy nor hepatosplenomegaly. He did not experience any
episodes of fever, night sweating, or weight loss during this period.
Skin biopsy from his chest revealed diffuse interstitial, peri-
vascular, and periadnexal inﬁltrations of monotonous medium-
sized blastic cells with slightly irregularly shaped nuclei and ﬁnen. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A, B) Multiple bruise-like or violaceous inﬁltrated patches and plaques on the trunk and face. (C) Close-up view of the bruise-like plaque on the chest.
Y.-H. Chou et al. / Dermatologica Sinica 32 (2014) 101e106102chromatin in the dermis. The epidermis was spared with a grenz
zone. Neither angiocentrism nor necrosis was present. Erythrocytes
extravasation and a fewmitotic ﬁgureswere also present (Figure 2).
On immunohistochemical staining, tumor cells were positive for
CD4, CD56, and leukocyte common antigen (CD45), and negative
for CD3, CD20, CD30, CD45RO, lambda/kappa light chain, epithelial
membrane antigen, pancytokeratin (AE1/AE3), and myeloperox-
idase. In addition, the tumor cells were also positive for CD123
(Figure 3). In situ hybridization for EBV-encoded small nuclear RNA
was negative. A biopsy from his right nasopharyngeal tissue also
revealed inﬁltration of diffuse medium-sized lymphoid cells that
were positive for CD4, CD56, and CD123 (Figure 4), and negative for
CD3 and EBV-encoded small nuclear RNA.
Laboratory examination showed a normal complete blood
cell count with no leukocytosis and no thrombocytopenia. The
biochemistry proﬁle, including electrolytes, lactic dehydrogenase,Figure 2 Skin biopsy from the chest. (A) Diffuse interstitial, perivascular, and periadnexa
epidermis is spared with a grenz zone. Neither angiocentrism nor necrosis is present (hem
shaped nuclei and ﬁne chromatin in the periadnexal area. Mitotic ﬁgures are occasionallyalkaline phosphatase, antinuclear antibody, hepatic and renal
function tests, coagulation proﬁle, and urine analysis, was all within
normal ranges.
Serology tests for human immunodeﬁciency virus, rapid plasma
regain, hepatitis A/B/C viruses, and human T-cell leukemia virus
type I showed negative results. Chest X-ray and cardiac echo
revealed no abnormalities. Peripheral blood smear and bone
marrow biopsy revealed no conspicuous neoplastic cell in-
ﬁltrations. Whole body computed tomography revealed thickened
soft tissue in his nasopharyngeal mucosa and in both pharyngeal
tonsils with no conspicuous lymphadenopathy and no deﬁnite
distant metastasis.
Based on the typical clinical features, histopathology, and
immunohistochemical studies, a diagnosis of BPDCN with skin
and nasopharynx involvement was made. The patient was then
referred to the hemato-oncology ward to undergo CHOP treatmentl inﬁltration of lymphoblastic-like cells in the dermis and subcutaneous tissue. The
atoxylin and eosin, 1.25). (B) Monotonous medium-sized blastic cells with irregularly
observed (hematoxylin and eosin, 400).
Figure 3 Immunohistological staining results of skin biopsy are positive for (A) CD4 with dendritic cytoplasmic staining (arrow), (B) CD56, and (C) CD123, and negative for (D)
myeloperoxidase, (E) CD3, and (F) CD20. All images are at their original magniﬁcation (400).
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3 weeks for a total of eight cycles. After two cycles of CHOP, the
bleeding tendency from his nasal cavity stopped. A complete
response was achieved after chemotherapy, and the bruise-like
inﬁltrated patches and plaques regressed (Figure 5A and B). The
occurrence of ecchymosis on his body from scratching also
diminished during treatment (Figure 5C). Follow-up positron
emission tomographyecomputed tomography examination
revealed no other extracutaneous organ involvement. Finally, the
patient was regularly followed-up in our hematology outpatient
clinic, and received maintenance therapy of cyclophosphamide and
prednisolone.
Discussion
In 1994, Adachi et al4 described the ﬁrst case of BPDCN in a Japa-
nese male with cutaneous CD4þ lymphoma. Since then, Petrellaet al2 and other groups3 have reported additional cases and re-
characterized the immunophenotypic and histological features of
BPDCN. The nomenclature of such CD4þ/CD56þ neoplasms has
been continuously evolving due to uncertainties regarding their
true histogenesis. Further advanced research came with the
delineation of the pDCs by Grouard et al10, and the expression of
CD123 (IL-3 receptor a chain) of lymphoid cells by Lúcio et al.6
Subsequent studies revealed that many features that are common
in phenotypic and functional characterization between both pDCs
and CD4þ/CD56þ neoplasms, suggesting that the neoplasm was
derived or originated from precursors of pDCs.7
BPDCN is very rare, accounting for less than 1% of all acute
leukemia8 and 0.7% of cutaneous lymphomas.11 According to 2008
and 2009 annual reports from the Taiwan Cancer Registry, the
incidence of BPDCN is approximately 3e6 persons/year. There are
fewer than 250 cases described in the literature to date12,13, and
there are only a few reports of Taiwanese cases.13,14
Figure 4 Nasopharyngeal biopsy from the right nasal cavity. (A) Diffuse medium-sized lymphoid cell inﬁltration (hematoxylin and eosin, 400). (BeD) Immunohistological staining
results of the nasopharyngeal soft tissue are positive for (B) CD4, (C) CD56, and (D) CD123. All images are at their original magniﬁcation (400).
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female ratio of 3:1); however, rare congenital and pediatric cases
have also been reported.14,15 The mean age is 55 years at diagnosis
(ranging from 3 days to 96 years), and 76% of the patients are older
than 50 years.16
Skin lesions are the most common manifestation in nearly all
BPDCN patients. However, a few cases of patients initially pre-
senting with fulminant leukemia but lacking cutaneous lesions
have been reported.17 Bone marrow and/or peripheral blood and
lymph node involvement occurred in 60e90% and 40e50% of pa-
tients, respectively. Initial fulminant leukemia is less common (5e
20%), but the risk of leukemic dissemination when tumor pro-
gression or relapse is greater and is nearly always present in the
terminal stage of BPDCN. According to the literature review, more
than half of the patients had only cutaneous lesions at the time of
diagnosis.3
The cutaneousmanifestation of BPDCN can be either localized or
wide spread. Their appearance is variable and includes violaceous,
erythematous, red brown and/or purpuric patches, plaques, nod-
ules, and ulcerative lesions on the head, trunk, and extremities.9,18
The bruise-like inﬁltrated lesions, as observed in our case, could be
the early manifestation of neoplastic cell inﬁltrationwith red blood
cell extravasation in the skin.
The invasion of other mucosal sites is relatively infrequent
(about 10%).1 Other organs, such as the liver, spleen, nasopharynx,
tonsils, kidneys, and central nervous system have also been re-
ported to be involved in BPDCN. Systemic B symptoms are rare at
diagnosis.7 Few cases of BPDCN with nasopharyngeal lesions
denoted in the literature are often accompanied with lymph node
or blood involvement.3,19 However, our case showed both skin and
nasopharynx involvement, and no conspicuous systemic dissemi-
nation. Such clinical manifestations were rarely noted in the liter-
ature. This could be explained by the early diagnosis after a 1-
month period of skin and nasal manifestations in our case.Histologically, BPDCN shows diffuse monotonous inﬁltrates of
medium-sized lymphoblastoid cells with round-to-oval nuclei,
indistinct nucleoli, scanty cytoplasm, and ﬁnely dispersed chro-
matin, which resemble lymphoblasts or myeloblasts in the dermis
and sometimes the subcutis. There is generally no epidermo-
tropism, necrosis, or angioinvasion. The neoplastic cells are often
positive for CD4, CD56, CD43, and cutaneous lymphocyte-
associated antigen (CLA).20 Expression levels of terminal deoxy-
nucleotidyl transferase, CD33, CD68, and CD45RA are variable.3
These neoplastic cells also express the pDC associated antigens
CD123, BDCA-2/CD303, and TCL-1, and are negative for common
T-cell, B-cell, and myeloid cell lineage markers.1 It should be noted
that some CD4e or CD56e variants have been described for
BPDCN.21 The T-cell receptor gene is germline and rearrangement
is nonclonal. It should be differentiated from other blastic he-
matopoietic malignancies demonstrating positive of CD56 and
CD4.19 The distinction of cases of acute myeloid leukemia/myeloid
sarcoma that are CD4þ/CD56þ is difﬁcult. The tumors often ex-
press multiple myeloid markers such as myeloperoxidase exclu-
sively, whereas only minorities of them are weakly positive of
CD123.22 Therefore, detection of multiple myeloid markers other
than CD33 favors the diagnosis of acute myeloid leukemia/
myeloid sarcoma, whereas expression of multiple plasmacytoid
dendritic cell markers favors BPDCN. Extranodal NK/T-cell lym-
phoma, nasal type is histologically associated with angioinvasion
of tumor cells, EBV infection, and the absence of CD123 expres-
sion. Myeloid neoplasms with increased pDCs acumination at
nodal or extranodal sites often lack CD56 expression and are
morphologically mature. In our case, the coexpression of CD4,
CD56, and CD123 and lack of EBV infection in the nasal mucosa
helped us to clarify whether there is merely an increase in pDC
inﬁltrates in response to immune activation as well as in reactive
lymphoid hyperplasia,7 and to rule out nasal type NK/T-cell
lymphoma.
Figure 5 Complete response after chemotherapy. (A, B) The bruise-like and violaceous inﬁltrated lesions on the trunk and face are diminished. (C) No appearance of ecchymosis on
the trunk after scratching (arrow).
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vival is approximately 12e14 months, and the 5-year-survival
rate is 0e6%.23 The initial clinical presentation of BPDCN may
seem deceptively indolent and often responds to multiagent
chemotherapy. However, relapse with rapid extracutaneous
dissemination, with or without leukemia, occurs in the vast
majority of patients with an average disease-free time of 9e11
months.1 Reports of efﬁcacy of treatments in patients with
BPDCN indicate that acute lymphoblastic leukemia/lymphoma-
type therapy results in a better outcome than acute myeloid
leukemia-type therapy, despite a closer relationship between
pDCs and myeloid cells.24 Long lasting remissions or curable
cases have been rarely reported in pediatric patients and
younger patients who received aggressive acute leukemia type
therapy and allogeneic stem cell transplantation.15,25 A multi-
variate analysis from Bekkenk et al23 also revealed that an age
<40 years, high expression of deoxynucleotidyl transferase,
presentation of only cutaneous lesions, and aggressive treatment
using an acute leukemia protocol are associated with a more
favorable prognosis.
Our BPDCN case presented with early cutaneous manifestations,
including bruise-like lesions, which were accompanied by unusual
nasopharyngeal involvement. Although a complete response was
observed after initial chemotherapy with regression of nasal and
skin lesions, long-term follow-up is necessary due to the high
relapse rate, rapid leukemic dissemination, and poor prognosis of
the disease. Cutaneous lesions are often the ﬁrst prominent pre-
sentation of BPDCN and show a great variability in their morpho-
logic and phenotypic features.18 The diagnosis of BPDCN requires
exhaustive examination by expert clinicians and histopathologists.
Dermatologists should be aware of the clinical presentations of
such hematopoietic neoplasms because the early diagnosis of the
disease and appropriate treatment is important to improve the
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